Symplicity Spyral RND system demonstrates significant blood pressure reduction through three years.
Medtronic plc announced long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial, which were presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22) late-breaking featured clinical research sessions.
The data were also simultaneously published in The Lancet.
In the first 80 patients of the SPYRAL HTN-ON MED trial, the data demonstrated that patients who were prescribed anti-hypertensive medications and treated with the Medtronic Symplicity Spyral Renal Denervation (RDN) System continued to show durable, clinically significant blood pressure reductions through three years.
At three years: 18.7 mmHg reduction in RDN patients versus 8.6 mmHg in sham for 24-hour systolic ambulatory blood pressure (ABPM). 20.9 mmHg reduction in RDN patients versus 12.5 mmHg in the sham arm for office systolic blood pressure (OSBP).
Across the latest trials, consistent blood pressure reductions have been observed in patients with uncontrolled hypertension treated with the Medtronic Symplicity Spyral RDN system," said Felix Mahfoud, M.D., cardiologist at Saarland University Hospital in Homburg, Germany, and member of the SPYRAL HTN executive committee. "For the first time, we now have randomized data that demonstrates that in a typical patient population – hypertension patients who are on anti-hypertensive medications and treated with RDN – we are seeing the continued, long-term blood pressure lowering effect. Lowering blood pressure can have meaningful clinical results for patients, including a decrease in the risk of cardiovascular events."
The trial also demonstrated procedural and long-term safety with the Symplicity Spyral renal denervation catheter, with zero major device or procedural safety events through three years.
See- The Lancet; VOLUME 399, ISSUE 10333, P1401-1410, APRIL 09, 2022. "Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial."-Prof Felix Mahfoud, MD, David E Kandzari, MD. Prof Kazuomi Kario, MD, Prof Raymond R Townsend, MD, Prof Michael A Weber, MD, et al.Published:April 04, 2022DOI:https://doi.org/10.1016/S0140-6736(22)00455-X.
Related news and insights
Roche announced that the European Commission (EC) has granted approval of Polivy (polatuzumab vedotin) in combination with MabThera(rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
NICE- National Institute for Health and Care Excellence (UK) Guidance:1.1 Romosozumab (Evenity)from UCB + Amgen, is recommended as an option for treating severe osteoporosis in people after menopause who are at high risk of fracture, only if: they have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture) and the company provides romosozumab according to the commercial arrangement.